| The future of peptide‐based drugs DJ Craik, DP Fairlie, S Liras, D Price Chemical Biology & Drug Design 81 (1), 136-147, 2013 | 2220 | 2013 |
| MR1 presents microbial vitamin B metabolites to MAIT cells L Kjer-Nielsen, O Patel, AJ Corbett, J Le Nours, B Meehan, L Liu, M Bhati, ... Nature 491 (7426), 717-723, 2012 | 1372 | 2012 |
| Protease inhibitors: current status and future prospects D Leung, G Abbenante, DP Fairlie Journal of Medicinal Chemistry 43 (3), 305-341, 2000 | 1244 | 2000 |
| Cu (II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction X Huang, MP Cuajungco, CS Atwood, MA Hartshorn, JDA Tyndall, ... Journal of Biological Chemistry 274 (52), 37111-37116, 1999 | 1016 | 1999 |
| T-cell activation by transitory neo-antigens derived from distinct microbial pathways AJ Corbett, SBG Eckle, RW Birkinshaw, L Liu, O Patel, J Mahony, Z Chen, ... Nature 509 (7500), 361-365, 2014 | 845 | 2014 |
| Characterization of copper interactions with Alzheimer amyloid β peptides CS Atwood, RC Scarpa, X Huang, RD Moir, WD Jones, DP Fairlie, ... Journal of Neurochemistry 75 (3), 1219-1233, 2000 | 841 | 2000 |
| Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion RA Cherny, JT Legg, CA McLean, DP Fairlie, X Huang, CS Atwood, ... Journal of Biological Chemistry 274 (33), 23223-23228, 1999 | 673 | 1999 |
| Solution structure of amyloid β-peptide (1− 40) in a water−micelle environment. Is the membrane-spanning domain where we think it is? M Coles, W Bicknell, AA Watson, DP Fairlie, DJ Craik Biochemistry 37 (31), 11064-11077, 1998 | 656 | 1998 |
| Antigen-loaded MR1 tetramers define T cell receptor heterogeneity in mucosal-associated invariant T cells R Reantragoon, AJ Corbett, IG Sakala, NA Gherardin, JB Furness, Z Chen, ... Journal of Experimental Medicine 210 (11), 2305-2320, 2013 | 621 | 2013 |
| Histone deacetylases as regulators of inflammation and immunity MR Shakespear, MA Halili, KM Irvine, DP Fairlie, MJ Sweet Trends in Immunology 32 (7), 335-343, 2011 | 590 | 2011 |
| Function, structure and therapeutic potential of complement C5a receptors PN Monk, AM Scola, P Madala, DP Fairlie British Journal of Pharmacology 152 (4), 429-448, 2007 | 513 | 2007 |
| Proteases universally recognize beta strands in their active sites JDA Tyndall, T Nall, DP Fairlie Chemical Reviews 105 (3), 973-1000, 2005 | 488 | 2005 |
| Structure, function and pathophysiology of protease activated receptors MN Adams, R Ramachandran, MK Yau, JY Suen, DP Fairlie, ... Pharmacology & Therapeutics 130 (3), 248-282, 2011 | 476 | 2011 |
| Constraining cyclic peptides to mimic protein structure motifs TA Hill, NE Shepherd, F Diness, DP Fairlie Angewandte Chemie International Edition 53 (48), 13020-13041, 2014 | 441 | 2014 |
| Alpha-synuclein structure and Parkinson’s disease–lessons and emerging principles RM Meade, DP Fairlie, JM Mason Molecular Neurodegeneration 14 (1), 29, 2019 | 417 | 2019 |
| Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors D Leung, K Schroder, H White, NX Fang, MJ Stoermer, G Abbenante, ... Journal of Biological Chemistry 276 (49), 45762-45771, 2001 | 414 | 2001 |
| Protease inhibitors in the clinic G Abbenante, DP Fairlie Medicinal Chemistry 1 (1), 71-104, 2005 | 410 | 2005 |
| Orally absorbed cyclic peptides DS Nielsen, NE Shepherd, W Xu, AJ Lucke, MJ Stoermer, DP Fairlie Chemical Reviews 117 (12), 8094-8128, 2017 | 390 | 2017 |
| Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers A Rahimpour, HF Koay, A Enders, R Clanchy, SBG Eckle, B Meehan, ... Journal of Experimental Medicine 212 (7), 1095-1108, 2015 | 380 | 2015 |
| Single turn peptide alpha helices with exceptional stability in water NE Shepherd, HN Hoang, G Abbenante, DP Fairlie Journal of the American Chemical Society 127 (9), 2974-2983, 2005 | 370 | 2005 |
